바이오스펙테이터

바이오스펙테이터 Jongwon Jang 기자

The palnt 3 of Samsung Biologics that has its operation ahead in this year made a contract for the first bio pharmaceuticals.

On 22nd, Samsung Biologics made a public announcement that they had made a contract scaled about 16.6 million dollars with the standard of minimum purchase supply for commissioning the productions of clinical products with a pharmaceutical company in the U.S.

This contract is an order for commissioning of bio-products that are currently developing, and their end date of contract is maintained secret for their business management. However, the term of a contract will be publicized after December 31st of 2019.

Samsung Biologics said, “We are expecting an increase to a maximum of 148.17 million dollars for the minimum guarantee contract amount if the partner company is successful in developing the contracted product.”

This contract means something in a perspective of the first contract for this third palnt. This third palnt completed in November is 118,000 square meters, doubled the size of Seoul World Cup Stadium, and is the world's largest biopharmaceutical palnt based on a single palnt with a production capacity of 180,000 liters. This year, we are preparing for full-scale operation through work such as validation.

Kim Tae-han, president of Samsung Biologics, said, "This contract has a significant meaning by its first order as the third palnt." “And if the production volume increases in the future, we are considering transferring production from the palnt 1,2 to the third palnt. We expect the utilization rate to be raised faster than expected”.